Avalo Therapeutics, Inc. [AVTX]

Source: 

Company Overview

Avalo Therapeutics, Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β monoclonal antibody (“mAb”), targeting inflammatory diseases.